Oppenheimer Maintains Outperform on Orchard Therapeutics, Lowers Price Target to $34
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Kevin DeGeeter maintains an Outperform rating on Orchard Therapeutics (NASDAQ:ORTX) but lowers the price target from $37 to $34.
June 13, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Oppenheimer maintains Outperform rating on Orchard Therapeutics (ORTX) and lowers price target from $37 to $34.
The news of Oppenheimer maintaining an Outperform rating on ORTX indicates a positive outlook for the company. However, the lowering of the price target from $37 to $34 may create some uncertainty among investors, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100